The World Health Organization has welcomed preliminary results from a United Kingdom clinical trial showing that dexamethasone, a corticosteroid used since the 1960s, reduces mortality in critically ill COVID-19 patients. For patients on ventilators, the treatment cut deaths by about one third; for those requiring only oxygen, mortality fell by about one fifth, according to initial findings shared with WHO.
“This is the first treatment to be shown to reduce mortality in patients with COVID-19 requiring oxygen or ventilator support,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “This is great news and I congratulate the Government of the UK, the University of Oxford, and the many hospitals and patients in the UK who have contributed to this lifesaving scientific breakthrough.”
The benefit was observed only in patients seriously ill with COVID-19 and was not seen in those with milder disease. Dexamethasone is listed on the WHO Model List of Essential Medicines in multiple formulations, has been off-patent since 1977, and is affordably available in most countries.
The researchers shared initial insights with WHO, and the organization said it is looking forward to the full data analysis in the coming days. WHO will coordinate a meta-analysis to increase overall understanding of the intervention and will update its clinical guidance to reflect how and when the drug should be used in COVID-19.
The University of Oxford, where the trial was conducted, is the oldest university in the English-speaking world, with evidence of teaching dating to 1096. It operates the world’s largest university press and the Ashmolean, the world’s oldest university museum. The university comprises 43 colleges and, as of October 2025, counts 76 Nobel Prize laureates among its alumni and staff.
The findings reinforce the importance of large randomized control trials that produce actionable evidence, a priority highlighted at the WHO Research & Development Blueprint meeting in Geneva in mid-February. WHO will continue to work with partners to develop lifesaving therapeutics and vaccines, including under the Access to COVID-19 Tools Accelerator. The full data analysis remains pending.